Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Advancing Cath Lab Results With FFRangio Coronary Physiology Assessment
NCT05893498 · View on ClinicalTrials.gov ↗
Study Summary
To test whether FFRangio-guided treatment is non-inferior to conventional pressure wire-guided treatment in patients with coronary artery disease.
Conditions Studied
Interventions
- DEVICE FFRangio
- DEVICE FFR or NHPR
Study Locations (20)
California
- University of California San Diego Health — La Jolla
- VA- Long Beach Healthcare — Long Beach
- Keck Medicine of USC — Los Angeles
- UCLA Medical Center — Los Angeles
- Stanford University — Palo Alto
- VA - Palo Alto Healthcare — Palo Alto
- Kaiser Permanente San Francisco — San Francisco
- St. Joesph's Medical Center — Stockton
Florida
- HCA Florida JFK Hospital — Atlantis
- Cardiac & Vascular Institute — Gainesville
- University of Miami — Miami
- HCA Florida Northside Hospital — St. Petersburg
- Tallahassee Research Institute — Tallahassee
- University of South Florida — Tampa
Kansas
- Ascension Via Christi St. Francis — Wichita
- Kansas Heart Hospital — Wichita
Georgia
- Archbold Hospital — Thomasville
Illinois
- Carle Foundation Hospital — Urbana
Kentucky
- St. Elizabeth Healthcare — Edgewood
Maryland
- Medstar Union Memorial Hospital — Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,924 participants |
| Start Date | 2023-06-21 |
| Est. Completion | 2026-05 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05893498
The ClinicalTrials.gov registry entry for NCT05893498 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,924 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CathWorks, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Percutaneous Coronary Intervention appearing as the primary indexed condition, and to 2 interventions — of which FFRangio is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05893498 reports 20 study locations spanning 7 distinct geographic areas — top geographies include California, Florida, Kansas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05893498 about?
NCT05893498 is a clinical study titled "Advancing Cath Lab Results With FFRangio Coronary Physiology Assessment". To test whether FFRangio-guided treatment is non-inferior to conventional pressure wire-guided treatment in patients with coronary artery disease.
What is the current status of trial NCT05893498?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 1,924 participants. The study started on 2023-06-21. Estimated completion is 2026-05.
What conditions does trial NCT05893498 study?
This clinical trial studies the following conditions: Percutaneous Coronary Intervention. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05893498?
The interventions under investigation include: FFRangio (DEVICE), FFR or NHPR (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05893498?
This trial is sponsored by CathWorks, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05893498 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.